Followers | 32 |
Posts | 6637 |
Boards Moderated | 0 |
Alias Born | 08/11/2016 |
Wednesday, July 05, 2023 2:09:51 PM
Recent ALLR News
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock • GlobeNewswire Inc. • 05/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:29:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 01:13:42 PM
- Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) • GlobeNewswire Inc. • 04/17/2024 01:10:00 PM
- Allarity Therapeutics Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 04/04/2024 01:15:00 PM
- Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:38:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 12:15:55 PM
- Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/08/2024 12:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/08/2024 02:45:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:21:14 PM
- Allarity Therapeutics to Present at Biomarkers 2024 • GlobeNewswire Inc. • 02/28/2024 11:00:00 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 02/23/2024 09:09:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:03:25 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/02/2024 10:03:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:40:01 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/26/2024 10:07:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:24:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:29:17 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/15/2023 10:00:50 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM